X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB GSK PHARMA UNICHEM LAB/
GSK PHARMA
 
P/E (TTM) x 280.4 55.5 505.5% View Chart
P/BV x 0.6 11.0 5.9% View Chart
Dividend Yield % 2.6 2.6 100.3%  

Financials

 UNICHEM LAB   GSK PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
GSK PHARMA
Mar-18
UNICHEM LAB/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs3822,760 13.8%   
Low Rs2342,040 11.5%   
Sales per share (Unadj.) Rs116.3339.0 34.3%  
Earnings per share (Unadj.) Rs-18.941.4 -45.7%  
Cash flow per share (Unadj.) Rs-11.745.9 -25.6%  
Dividends per share (Unadj.) Rs5.0035.00 14.3%  
Dividend yield (eoy) %1.61.5 111.3%  
Book value per share (Unadj.) Rs381.0242.9 156.9%  
Shares outstanding (eoy) m70.3484.70 83.0%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.67.1 37.4%   
Avg P/E ratio x-16.357.9 -28.1%  
P/CF ratio (eoy) x-26.252.3 -50.2%  
Price / Book Value ratio x0.89.9 8.2%  
Dividend payout %-26.484.5 -31.3%   
Avg Mkt Cap Rs m21,668203,280 10.7%   
No. of employees `0002.3NA-   
Total wages/salary Rs m2,0065,234 38.3%   
Avg. sales/employee Rs Th3,587.8NM-  
Avg. wages/employee Rs Th880.0NM-  
Avg. net profit/employee Rs Th-583.7NM-  
INCOME DATA
Net Sales Rs m8,18028,715 28.5%  
Other income Rs m610545 111.9%   
Total revenues Rs m8,79029,260 30.0%   
Gross profit Rs m-1,3205,059 -26.1%  
Depreciation Rs m505380 132.9%   
Interest Rs m802 4,005.0%   
Profit before tax Rs m-1,2955,222 -24.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m331,892 1.8%   
Profit after tax Rs m-1,3313,508 -37.9%  
Gross profit margin %-16.117.6 -91.6%  
Effective tax rate %-2.636.2 -7.1%   
Net profit margin %-16.312.2 -133.2%  
BALANCE SHEET DATA
Current assets Rs m23,31821,815 106.9%   
Current liabilities Rs m4,63515,999 29.0%   
Net working cap to sales %228.420.3 1,127.6%  
Current ratio x5.01.4 368.9%  
Inventory Days Days12264 191.5%  
Debtors Days Days12119 650.0%  
Net fixed assets Rs m8,16312,475 65.4%   
Share capital Rs m141847 16.6%   
"Free" reserves Rs m26,66019,726 135.2%   
Net worth Rs m26,80120,573 130.3%   
Long term debt Rs m36 55.0%   
Total assets Rs m31,89039,475 80.8%  
Interest coverage x-15.22,612.0 -0.6%   
Debt to equity ratio x00 42.2%  
Sales to assets ratio x0.30.7 35.3%   
Return on assets %-3.98.9 -44.1%  
Return on equity %-5.017.1 -29.1%  
Return on capital %-4.526.2 -17.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,356564 772.4%   
Fx outflow Rs m07,429 0.0%   
Net fx Rs m4,356-6,865 -63.5%   
CASH FLOW
From Operations Rs m-1,1234,728 -23.8%  
From Investments Rs m16,487-1,042 -1,582.4%  
From Financial Activity Rs m-8,811-3,066 287.3%  
Net Cashflow Rs m6,552620 1,057.3%  

Share Holding

Indian Promoters % 50.1 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 15.1 10.2 148.0%  
FIIs % 3.0 23.8 12.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 15.4 205.8%  
Shareholders   20,176 102,036 19.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   WOCKHARDT LTD.  J.B.CHEMICALS  CIPLA  ELDER PHARMA  VENUS REMEDIES  

Compare UNICHEM LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 20, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - DISHMAN PHARMA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS